PMID- 21956220
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20161125
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 87
IP  - 1
DP  - 2012 Jan
TI  - A 10-year experience with treatment of high and standard risk Hodgkin disease: 
      six cycles of tailored BEACOPP, with interim scintigraphy, are effective and 
      female fertility is preserved.
PG  - 32-6
LID - 10.1002/ajh.22187 [doi]
AB  - Therapy of Hodgkin lymphoma (HL) is designed to prolong survival and minimize 
      toxicity. A total of 124 patients with newly diagnosed HL and adverse prognostic 
      factors were prospectively studied between July, 1999 and August, 2005. Patients 
      with early unfavorable and advanced disease were eligible for the study. Patients 
      were assigned to therapy based on international prognostic score (IPS). Those 
      with IPS >/= 3 received three cycles of escalated BEACOPP (EB). All others received 
      two cycles of standard BEACOPP (SB). Subsequent therapy was prospectively 
      assigned according to early interim GA(67) or positron emission tomography 
      (PET)/computerized tomography (CT). Four cycles of EB or SB were administered 
      following a positive or negative scan, respectively. Complete remission rate, 
      10-year progression free (PFS), and overall survival (OS) were 97, 87, and 88%, 
      respectively, at a median follow-up of 89 months (5-144). PFS and OS were similar 
      in both groups. Fertility status was assessed in 38 females aged <40 years; 94% 
      of females younger than 40 years preserved their cyclic ovarian function. 
      Nineteen conceived during follow-up for 30 pregnancies, delivering 24 babies. 
      Deliveries were reported up to 7 years from diagnosis. Predictive value of 
      negative interim Ga(67) or PET/CT was 87 and 93%, respectively. Six cycles of 
      tailored BEACOPP, for patients with adverse prognostic factors, provide 
      encouraging long-term PFS and OS, and fertility is preserved in most females.
CI  - Copyright (c) 2011 Wiley Periodicals, Inc.
FAU - Dann, Eldad J
AU  - Dann EJ
AD  - Department of Hematology and Bone Marrow Transplantation, Rambam Health Care 
      Campus, Haifa, Israel. e_dann@rambam.health.gov.il
FAU - Blumenfeld, Zeev
AU  - Blumenfeld Z
FAU - Bar-Shalom, Rachel
AU  - Bar-Shalom R
FAU - Avivi, Irit
AU  - Avivi I
FAU - Ben-Shachar, Menachem
AU  - Ben-Shachar M
FAU - Goor, Odelia
AU  - Goor O
FAU - Libster, Diana
AU  - Libster D
FAU - Gaitini, Diana
AU  - Gaitini D
FAU - Rowe, Jacob M
AU  - Rowe JM
FAU - Epelbaum, Ron
AU  - Epelbaum R
LA  - eng
PT  - Journal Article
DEP - 20110928
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 11056-06-7 (Bleomycin)
RN  - 35S93Y190K (Procarbazine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - BEACOPP protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Etoposide/therapeutic use
MH  - Female
MH  - *Fertility Preservation
MH  - Hodgkin Disease/diagnostic imaging/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging
MH  - Positron-Emission Tomography
MH  - Prednisone/therapeutic use
MH  - Procarbazine/therapeutic use
MH  - Prognosis
MH  - Sex Factors
MH  - Survival Analysis
MH  - Tomography, X-Ray Computed
MH  - Vincristine/therapeutic use
MH  - Young Adult
EDAT- 2011/10/01 06:00
MHDA- 2012/05/05 06:00
CRDT- 2011/09/30 06:00
PHST- 2011/07/27 00:00 [received]
PHST- 2011/08/31 00:00 [revised]
PHST- 2011/09/06 00:00 [accepted]
PHST- 2011/09/30 06:00 [entrez]
PHST- 2011/10/01 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
AID - 10.1002/ajh.22187 [doi]
PST - ppublish
SO  - Am J Hematol. 2012 Jan;87(1):32-6. doi: 10.1002/ajh.22187. Epub 2011 Sep 28.